Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RECT | Rectitude | $2.39 | $1.19 | 99.17% | 3.7M | $17M | $1.00$5.21 |
| BTM | Bitcoin Depot | $4.05 | $1.42 | 53.99% | 60.7K | $29M | $1.91$48.16 |
| ALMU | Aeluma | $15.07 | $4.31 | 40.06% | 235.5K | $194M | $6.08$25.88 |
| RVMD | Revolution Medicines | $134.15 | $37.72 | 39.12% | 377.8K | $19B | $34.00$135.81 |
| XNDU | Xanadu Quantum Technologies | $12.23 | $3.27 | 36.50% | 1.2M | $203M | $6.97$12.97 |
| MNTS | Momentus | $4.75 | $1.27 | 36.49% | 5.3M | $20M | $3.11$43.55 |
| LICN | Lichen International | $4.29 | $1.10 | 34.33% | 121.3K | $52M | $2.57$8.28 |
| HURA | TuHURA Biosciences | $2.91 | $0.64 | 28.19% | 35.8K | $144M | $0.41$4.44 |
| ALLO | Allogene Therapeutics | $3.43 | $0.71 | 26.10% | 1.6M | $663M | $0.86$4.46 |
| SYRE | Spyre Therapeutics | $64.44 | $13.15 | 25.64% | 3.8M | $4.0B | $12.04$75.00 |
| OPTX | Syntec Optics | $11.70 | $2.35 | 25.13% | 121.1K | $346M | $1.04$12.20 |
| BNAI | Brand Engagement Network | $52.53 | $10.47 | 24.88% | 615K | $245M | $1.18$86.28 |
| IMA | ImageneBio | $6.07 | $1.17 | 23.83% | 17.1M | $55M | $3.94$18.00 |
| HCAI | Huachen Ai Parking Management Technology | $7.86 | $1.47 | 22.92% | 59.7K | $223M | $3.96$318.45 |
| MTC | MMTec | $6.99 | $1.27 | 22.20% | 1.3K | $570M | $0.25$7.00 |
| TBRG | TruBridge | $21.72 | $3.74 | 20.80% | 17.5K | $268M | $13.88$26.74 |
| ORCU | Direxion Shares ETF Trust - Daily Orcl Bull 2x Etf | $10.09 | $1.69 | 20.11% | 1.3M | - | $7.99$27.62 |
| ORCX | Tidal Trust II - Defiance Daily Target 2x Long Orcl ETF | $28.30 | $4.73 | 20.07% | 3.4M | - | $22.37$181.59 |
| CLLS | Cellectis | $4.25 | $0.66 | 18.38% | 5.2K | $260M | $1.33$5.48 |
| HHS | Harte Hanks | $2.79 | $0.43 | 18.19% | 29.3K | $18M | $2.22$5.39 |
| CRWG | Themes ETF Trust - Leverage Shares 2x Long Crwv Daily ETF | $4.75 | $0.73 | 18.04% | 39.6M | - | $1.80$19.63 |
| NBIG | Themes ETF Trust - Leverage Shares 2x Long Nbis Daily ETF | $16.34 | $2.47 | 17.81% | 864.6K | - | $4.51$19.45 |
| NETG | Themes ETF Trust - Leverage Shares 2x Long Net Daily ETF | $9.01 | $1.36 | 17.78% | 356.3K | - | $7.40$15.17 |
| CRCG | Themes ETF Trust - Leverage Shares 2x Long Crcl Daily ETF | $2.67 | $0.40 | 17.67% | 20.9M | - | $0.95$20.92 |
| NBIL | GraniteShares ETF Trust - GraniteShares 2x Long Nbis Daily ETF | $23.16 | $3.43 | 17.39% | 1.5M | - | $6.37$38.58 |
| BCG | Binah Capital Group | $2.06 | $0.30 | 17.05% | 330.1K | $29M | $1.36$3.44 |
| GDEV | Gdev | $16.04 | $2.32 | 16.91% | 2K | $249M | $10.19$42.20 |
| BBNX | Beta Bionics | $10.34 | $1.48 | 16.70% | 610.5K | $393M | $8.80$32.71 |
| HIMZ | Tidal Trust II - Defiance Daily Target 2x Long Hims ETF | $22.94 | $3.13 | 15.80% | 892.8K | - | $12.38$780.77 |
| MOVE | Corvex | $12.61 | $1.71 | 15.69% | 51.8K | $18M | $3.44$25.68 |
| CDT | Cdt Equity | $4.68 | $0.60 | 14.71% | 52.7K | $19M | $3.64$3,030.00 |
| VACHU | Voyager Acquisition Corp. | $10.40 | -$1.10 | -9.56% | 1 | $329M | $10.08$14.41 |
Related Articles
Featured Article
This 2020 Biotech IPO Is Poised to Break Out in 2021
Patrick Bafuma|Apr 2, 2021
Revolution Medicines' leading compound is shaping up to be a platform in a pill.
4 Companies That Could Upend the Pharma Industry
James Halley|Jul 29, 2020
Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.
Investors Scrambled to Buy This Biotech IPO
Jim Crumly|Feb 21, 2020
Shares of cancer-specialist Revolution Medicines soared on its first day of public trading.
These Gene-Editing Pioneers Are Making Bold Bets in Agriculture
Maxx Chatsko|Jan 18, 2020
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine?
Maxx Chatsko|Dec 23, 2019
The gene editing company published a proof-of-concept for "smart" immunotherapies. The idea may catch on.
3 IPOs That Have More Than Tripled in 2019
Rick Munarriz|Jul 1, 2019
Beyond Meat, MMTec, and ShockWave Medical are the three hottest IPOs through the first half of this year.
2 Big Biotech Stock Upgrades: Can They Reach These Targets?
Cory Renauer|May 5, 2019
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
George Soros Bought This Under-the-Radar Biotech Stock: Should You?
George Budwell, PhD|Aug 20, 2018
Soros Fund Management picked up a healthy stake in rare-disease and cancer drugmaker Aeglea BioTherapeutics in the second quarter.
Is Cellectis SA Stock a Buy Now?
Cory Renauer|Apr 7, 2018
Despite getting passed along to a biotech start-up, Cellectis could have a bright future.
Can Been-There Biotech Entrepreneur Arie Belldegrun Do It Yet Again?
Todd Campbell|Apr 6, 2018
Belldegrun's Allogene Therapeutics has just inked a transformative deal to land Pfizer's CAR-T cancer gene therapy program.
